METiS TechBio Raises $269.5M in Hong Kong IPO on May 13, Shares Jump on Debut

According to South China Morning Post, AI drug design startup METiS TechBio raised HK$2.11 billion (US$269.5 million) in its Hong Kong IPO on May 13, with shares jumping on debut amid strong demand for AI-related stocks.

The company sold 201.23 million shares at HK$10.50 (US$1.3) each. Eighteen cornerstone investors, including BlackRock, UBS Asset Management Singapore, and Mirae Asset Securities, subscribed a combined US$148 million with a six-month lock-up agreement. METiS became the third AI drug developer to list in Hong Kong after XtalPi (June 2024) and Insilico Medicine (December 2025).

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Comment
0/400
No comments